DOI: 10.36347/sjams.2017.v05i03.026

Pages: 827-834

Several chronic infections like HIV have reported an increased prevalence of metabolic syndrome. With the advent of highly active antiretroviral therapy (HAART), the prognosis of HIV patients have improved dramatically. However, multiple unforeseen complications have been seen in HIV patients on long-term HAART including metabolic syndrome. As multiple drugs are used for HAART with different backbones, the incidence of metabolic syndrome has been shown to vary with different regimes of antiretroviral therapy (ART), though the role of NNRTI-based ART has not been clearly implicated in the genesis of metabolic syndrome in treated HIV patients. The present study aims to study the effects of NNRTI on different components of metabolic syndrome in HIV patients. In this cross-sectional study, 70 HIV patients treated with ART (aged 20-50 years) and 64 ART-naive patients were included as control group. Metabolic syndrome prevalence was examined using the US Metabolic syndrome prevalence was examined using the US National Cholesterol Education Program Adult Treatment Panel III (ATP III) (NHLBI updated definition 2005) criteria. All patients received NNRTI-based ART (either Efavirenz or Nevirapine, in the recommended doses) for a mean period of 14 months. Statistical testing was conducted with the statistical package for the social science system version SPSS 17 and Graph PadInStat. Statistical significance was set at p< 0.05.